To study the pharmacokinetics of articaine and its metabolite articainic acid, in patients undergoing intravenous regional anaesthesia. Methods Ten patients (three male, seven female, ASA class 1-2), scheduled for surgery of the hand or forearm were included in the study. Articaine (40 ml, 0.5% solution (200 mg) was injected over 30 s. In total fifteen arterial blood samples were taken; one before injection and then at 10 min intervals, starting 10 min after completion of injection, until the tourniquet was released; thereafter blood samples were drawn at intervals of 1, 5, 10, 15, 20, 25, 30, 45, 60, 75 and 90 min. The tourniquet was released 30 min after completing the injection. Results During tourniquet application and regional analgesia of 30 min duration, 55% of articaine was hydrolysed by plasma (20%) and tissue (35%) esterase activity to the metabolite articainic acid. After releasing the tourniquet, articaine and its metabolite appeared in the blood; articaine was rapidly eliminated with a t 1/2z of approximately 60 min. The plasma concentration of the metabolite articainic acid was the sum of the amount formed during IVRA (55%) and the amount formed after tourniquet release (45%). Conclusions Articaine is a safe agent for intravenous regional anaesthesia (IVRA) with rapid onset of good surgical anaesthesia. During tourniquet application and regional analgesia, 55% of the administered dose is already hydrolysed, thus reducing the chance of side effects after tourniquet release.
Introduction utilization [17, 18] .
There are only limited data on the pharmacokinetics of For intravenous regional anaesthesia (IVRA), different local anaesthetics have been used [1] . At the beginning of the articaine and no report is available relating to IVRA. The aim of this investigation was to study the pharmacokinetics 20th century, Bier used 40 ml 0.5% procaine [2] . Lignocaine was first used in 1963, and prilocaine in 1964 [3] . The use of articaine and its metabolite, articainic acid, in 10 patients undergoing intravenous regional anaesthesia. of chloroprocaine may lead to thrombophlebitis [1] , venous irritation and urticaria [4] . Bupivacaine is contraindicated because of potential cardiotoxicity and fatal complications Methods have been reported following intravenous injection [5] [6] [7] [8] , a situation that exists with this technique when the tourniquet Protocol is released at the end of the surgical procedure.
The study was approved by the Ethics Committee of the The ideal agent for IVRA provides rapid onset of good Medisch Spectrum Twente, and written informed consent surgical anaesthesia with a low cardiotoxicity. Articaine was obtained from 10 patients (ASA class 1-2, classification is a safe local anaesthetic agent as previously reported according to the American Society of Anesthesiologists), [9, 10] and its metabolite has no effect on heart rate and scheduled for surgery of the hand or forearm. blood pressure [11, 12] . Articaine ((±)-3-n-propylamineThree men and seven women were included in the study. propionylamido-2-carbomethoxy-4-methylthiophen hydro-
The mean (±s.d.) body weight was 70.5±8.4 kg, and age chloride) was first investigated clinically in 1974 [13] [14] [15] [16] 50.2±14.2 years. and is now used (4% with adrenaline 15200 000) in dentistry for infiltration and conduction anaesthesia. The very fast onset of the block, the excellent quality of the anesthesia, Patient preparation the reduced toxicity and the short duration of action, owing
No premedication was given. An 18G cannula was introduced into a suitable vein in the dorsum of the hand of the arm to be treated. A similar cannula was introduced arm was cannulated for continuous invasive blood pressure 1, 5, 10, 15, 20, 25, 30, 45 Plasma (0.3 ml) was deproteinized with acetonitrile Any skin reactions or subjective complaints were noted. The development of sensory blockade over the distributions (0.3 ml), vortexed and centrifuged at 3000 g. 50 ml was injected onto the column. of the median, radial and ulnar nerves was assessed by pinprick.
The recovery of articaine added to human plasma in the concentration range 0.04-8.0 mg ml −1 was 64.5±2.8% Onset of the surgical analgesia was defined as the period from the end of the injection of the local anaesthetic to the (mean ±s.d., n=8). The recovery for the metabolite was 82.9±3.7% in the concentration range 0.1-20.0 mg ml −1 . loss of pinprick sensation in the distribution of all three nerves.
The inter-and intra-day coefficients of variance for articaine (0.040 mg ml −1 -8.0 mg ml −1 ) and articainic acid In total fifteen arterial blood samples were taken; one before injection and then at 10 min intervals, starting 10 min (0.1-20.0 mg ml −1 ) were less than 5%.
The lowest limit of quantitation for both compounds in after completion of injection, until the tourniquet was released; thereafter blood samples were drawn at intervals of serum was 0.04 mg ml −1 at a signal-to-noise ratio 351. 
Pharmacokinetics
Pharmacokinetic parameters were calculated from the fitted plasma concentration-time curve (r 2 >0.98) according to a two-compartment model using the MW/Pharm computer package (MediwareA, Groningen, The Netherlands) [20] . The elimination half-life (t 1/2,z ) values were calculated from ln2/l z , where l z is calculated by log-linear regression analysis of the terminal log-linear phase.
AUC(0,t ) was the area under the plasma concentrationtime curve and was calculated using the linear trapezoidal rule to t=90 min.
Total body clearance (CL) is described as CL= Dose/AUC(0,t). The volume of distribution in the central compartment V d =Dose/C o . V z =the volume of distribution during elimination=CL/l z . V ss , the volume of distribution at steady-state=Dose . AUMC(0,t)/AUC(0,t) 2 .
Mean residence time (MRT)=AUMC(0,t)/AUC(0,t ), where AUMC(0,t) is the area under the moment curve from zero to t=90 min.
C max =maximum plasma concentration, t max =time at which C max occurs, t lag =lag time, t 1/2,abs =half-life of absorption, t 1/2,a =half-life of distribution phase, t 1/2,z = half-life of elimination phase.
Results

Clinical response
The onset time of the local anaesthetic action of articaine was 2.5±1.1 min.
In all patients satisfactory surgical conditions, evidenced by good sensory blockade, were reached within 10 min, and no additional analgesics were required. There was no trend towards a fixed sequence, radial-median-ulnar in the development of sensory blockade. None of the patients exhibited objective symptoms of toxicity, either local or systemic, during injection of articaine, nor were there any subjective complaints. No changes in blood pressure, heart rate or oxygen saturation were observed at any time during the procedure, nor after deflation of the tourniquet. Toxic symptoms and subjective complaints were absent following tourniquet release, nor were any changes recorded on the ECG when analyzed from the 12-lead registration. Figure 1 shows the mean plasma concentration-time curves of articaine and its metabolite articainic acid in 10 patients after releasing the tourniquet. Plasma concentrations of both compounds were zero before releasing the tourniquet.
Pharmacokinetics
The plasma concentration-time curve of the metabolite articainic acid showed, during the first 100 min after tourniquet release, a plateau value with a mean concentration of 3 mg ml . Table 1 shows the individual and mean values of the pharmacokinetic parameters of articaine. Articaine is eliminated biexponentially with a t 1/2,a of 4.6±2.5 min and a t 1/2,z of 58.8±38.7 min (mean±s.d.). Table 2 shows the individual and mean values of the pharmacokinetic param- Table 1 Pharmacokinetic parameters of articaine after i.v. administration of 40 ml 0.5%=200 mg=0.704 mmol. eters of the metabolite articainic acid. The difference d.) of articaine, and its metabolite articainic acid (total and formed) after IVRA administration of 40 ml 0.5% (=200 mg=704 mmol). Calculated from individual plasma concentration-time data (n=10). 1 of total articaine (A)+articainic acid (Ac). 2 of total articainic acid.
in AUC values between total and plasma formed articainic This explains the high initial value of the plasma concentration of the metabolite. After i.v. and epidural acid represents the amount and percentage of articainic acid formed in the exsanguinated arm during tourniquet administration of articaine, it takes 1 h to reach the C max of the metabolite [18, 19] . The metabolite is rapidly eliminated application (55.1±7.1%). Table 3 summarizes the AUC values of articaine and its from the body by renal excretion (80%) and glucuronidation (20%) and shows an intrinsic t 1/2,z value of 60 min [11, 12] . metabolite articainic acid, as well as the percentages of articainic acid formed during IVRA (55.1±7.1%) and after After tourniquet release the remaining articaine is further hydrolysed by plasma esterase (45%). tourniquet release (44.9±7.3%).
From the plasma concentration-time curve of articainic acid formed after tourniquet release, the calculated t 1/2,abs Discussion showed a large variation (6.08-321.7 min; 132% CV) which was due to three patients (numbers 2,6,7) having prolonged The absorption of articaine from the exsanguinated forearm after releasing the tourniquet was so fast that the maximum absorption times. In these three patients the t 1/2,abs (246.0±85.6 min; 34.8% CV) was 12 times larger than in plasma concentration was already achieved at the first sample at 1 min. Thereafter articaine was eliminated according to a the other seven patients (20.21±7.22 min; 35.7%CV; P= 0.0167). This difference may reveal a difference in the biexponential decay after i.v. administration with t 1/2,a of 4.6±2.5 min, and a t 1/2,z of 58.8±38.7 min. At the first efficiency of intravenous injection or show substantially different tissue distribution. In the seven patients, the plasma sample at 1 min, the metabolite articainic acid was present at a relatively high concentration of injection is purely intravenous, with relatively little diffusion in the tissues, so that after tourniquet release, the total 3.1±0.46 mg ml −1 , which remained nearly constant during the whole sampling period of 90 min. A similar behaviour amount is swept with the incoming blood stream into the general circulation. When in the other three patients the of articainic acid has been reported earlier [18, 19] , the plasma concentration-time curve of the metabolite showed intravenous injection is less perfect (in part intramuscular), the absorption from tissues takes more time. a broad maximum, which started to decline 2 h after administration of the parent drug. The intrinsic t 1/2,z of the metabolite was 60 min [11, 12] , when the metabolite was Clinical implication administered as the study compound.
Articaine is a suitable and safe agent for IVRA with rapid The plasma concentration-time curve of the metabolite onset of good surgical anaesthesia. During tourniquet shows two processes. First there is the high initial concenapplication and regional analgesia, 55% of the administered tration, which starts to decline for 10 min, thereafter the dose is already hydrolysed, thus reducing the chance of side concentration rises again to an apparent 'plateau' value.
effects after tourniquet release. It has to be determined When the intrinsic half-life of 60 min of articainic acid is whether the metabolite articainic acid possesses analgesic inserted at the C 0 value of 3.08 mg ml −1 , and the concenand local anaesthetic properties, as this compound is present trations of this line subtracted from the overall plasma in high concentrations in plasma. After releasing the concentration of articainic acid, the plasma concentrationtourniquet, articaine is rapidly eliminated with a t 1/2,z of time curve of the metabolite after tourniquet release approximately 60 min. emerges. When the areas under the 'corrected' plasma concentration-time curves are calculated (AUC(0,t) mmol l −1 min) the relative percentages of the different processes References can be visualized as demonstrated in Table 2 .
